What Does SWOG Have to Offer an Early Career Investigator? My Perspective



Cathy Tangen Deputy Director SWOG Statistical Center Faculty stat: GU, Prevention





# Outline

- Getting Acquainted, Steps to Take
- Potential Opportunities
- Resources and tools available on SWOG.org website
- Funding Opportunities in SWOG, The Hope Foundation
- Mentoring, Networking, Committees







### Committees

#### 1. How can an investigator join a committee?

A nomination letter from the institution Principal Investigator and a current copy of the investigator's CV must be submitted to the SWOG NOC in San Antonio at <u>member@swog.org</u>.

If the investigator is not yet a SWOG member, a credentialing request must be submitted either through RUMS or NCORPSYS in order to activate SWOG membership at the institution. The nomination letter from the PI and copy of the CV may be submitted simultaneously with the credentialing request.

See <u>SWOG Policy Memorandum #8</u> for additional information on committee membership.

#### 2. How do I join SWOG distribution lists?

• To request to be included on the SWOG bi-monthly protocol and general updates distribution list, E-mail: <a href="mailto:member@swog.org">member@swog.org</a>.

• To request to be included on the SWOG CRA Quarterly Newsletter distribution list, login to the SWOG CRA Workbench and then click on the "Join the CRA Mailing list" link OR paste the following link into browser after login (<u>https://txwb.crab.org/TXWB/ListServe.aspx</u>).

• To subscribe to our weekly <u>Front Line</u> (the group chair's Friday blog post) or to the SWOG TM Link of the Week, contact <u>communications@swog.org</u>.







# SWOG.org, public and private side



## Public

- Meeting information
- Leadership
- Policies and Procedures
- Information about Membership
- Clinical trials, general information

## **Members Only**

- Roster of members
- Access to trial search tool
- Protocols, CRFs, Report of Studies
- Newsletters, participate in SWOG meetings





# How to Get Integrated in SWOG

- Z
- Get on email lists, invitations for regular committee (zoom) meetings
- Attend the semi-annual Group Meeting regularly
  - Disease committee open and working group, but also AYA, VA, RT, Surgery, Community Rep, DEI committees/working groups, recruitment/retention
- Introduce yourself to disease committee leadership
- Offer to help with anything
- Share your opinion
- Enter patients on NCTN trials! (crediting SWOG helps)
- Seek relationships with SWOG mentors





## **Upcoming Group Meetings**

## Spring 2024 SWOG Group Meeting

April 4-7, 2024 Hyatt Regency Seattle Seattle, Washington



Wednesday-Saturday, April 3-6	Group Meeting
Wednesday, April 3	CRA Clinical Trials Training Course
Thursday, April 4	Plenary I; Exhibits
Friday, April 5	Plenary II; Exhibits








# Opportunities on SWOG Clinical Trials for Early Career Investigators

- Back-up study chair, answer treatment and AE questions from sites, review eligibility criteria
- Patient Reported Outcomes: sub-study chair





## SWOG Champion (represent SWOG on another NCTN-group trial)







#### SWOG-CHAMPIONED INTERGROUP STUDIES

STUDYID Accrual	STUDY NAME	Phase	Open Date	Coop grp	SWOG/Total Accrual	Champion
EA8134 N=200	InPACT		9/8/2017	ECOG- ACRIN	12/82	Dr. Curtis Pettaway
EA8171 N=852	Multiparametric MRI (mpMRI) for Preop Staging and Treatment Planning for Newly-Diagnosed Pros Cancer	II	7/9/2018	ECOG- ACRIN	87/784	Dr. Michael Liss
EA8173	Pros, 18F-DCFPyL PSMA-based PET/CT for directed ablative RT in patients with biochem recur and oligometastases	II	Target 1/18	ECOG- ACRIN	Presented to prostate task force 7/17	Dr. Jing Zeng
EA8183 N=810	A Phase III Double Blinded Study of Early Intervention After RADICAI ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)	III	12/09/2020 CLOSED 2/09/2023	ECOG- ACRIN	4/27	Dr. Tanya Dorff
EA8185 N=102	Phase 2 Study of Bladder- Sparing Chemoradiation with Durvalumab in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)	I	8/25/2020 CLOSED 10/02/2023	ECOG- ACRIN	1/11	Dr. Timur Mitin & Dr. Joshua Meeks
EA8191 N=804	PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence		10/08/2020	ECOG- ACRIN	23/209	Dr. Volkan Beylergil & Dr. Evan Yu
EA8192 N=249	Blad, High Grade UTUC, Durvalumab + Chemo Prior to Nephroureterectomy	11/111	5/06/2021	ECOG- ACRIN	2/32	Dr. Shuchi Gulati
EA8212 N=870	Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)	III	12/01/2022	ECOG- ACRIN	53/205	Dr. Sia Daneshmand & Dr. Mary Beth Westerman
GU002 N=612	Adj RT + AD Following Rad Prostatectomy +/- Adj Docetaxel	11/111	12/30/2016 CLOSED 9/06/2022	NRG	4/165	Dr. David Raben








a National Cancer Institute program
A program of the National Cancer Institute
of the National Institutes of Health

These options are only available if you are logged in as a member

## **Member Resources**



# **Clinical Trials**

Keywords/SWOG Study Number	Area of Research		
bladder	Any 🗸	SEARCH Fewer filters -	
Accrual Status Li	mit to SWOG Trials		
Any Open Olosed O	All Trials 💿 SWOG Trials Only Sho	ow only published studies	
Study Type	Treatment	Study Chair	Participating Institution
Treating for Cancer 🗸 🗸	Any ~		
Phase	Cancer Control Subcommittee	Study Sponsor	
Any	Any	Any	FDA Registration Trial
			Uses PRO Forms

Open Phase	S1806 SWOG Clinical Trial Number	Create a Saved List
89%		ial of Concurrent Chemoradiotherapy with or Without $\ominus$ ed Muscle Invasive Bladder Cancer.
	Research Committee(s)	Genitourinary Cancer
Accrual	Study Chair(s)	Parminder Singh, MD
	Activated	04-19-2019
Closed Phase	<b>S1602</b> SWOG Clinical Trial Number	Create a Saved List
100%		Trial to Evaluate the Influence of BCG Strain Differences → Intradermal BCG Before Intravesical Therapy for BCG-Naïve Invasive Bladder Cancer
Accrual	Status Notes	There is a monthly call for coordinators who have questions about this study. Send an email to S1602question@swog.org to be added.
	Research Committee(s)	Genitourinary Cancer
	Study Chair(s)	Robert Scott Svatek MD

S1602 SWOG clinical trial number

Closed

Phase

100%

Accrual

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

BCG Strain Differences and BCG vaccination in High-Grade

There is a monthly call for coordinators who have questions

about this study. Send an email to \$1602question@swog.org

Non-Muscle Invasive Bladder Cancer

ALLIANCE, ECOG-ACRIN, NRG, SWOG

Robert Scott Svatek, MD

to be added.

02/07/2017

12/15/2020

Abbreviated Title

Status Notes

Activated

Participants


Study chair(s)

Closed

Create a Saved List Email 🖂 Print ( Download Documents Protocol & Model Consent Form Most Recent Updates Archive  $(\rightarrow)$ Safety Reports BCG BCG Tokyo-172 Strain

### **Reports & Approvals**


ROS REPORT



	·	Documents			,
9	🛓 Memorandum: Intradermal Supply	Supplemental Documents	01-Apr-2021	PDF	02-Apr-2021
10	Memorandum: SWOG DSMC Meeting Minutes – October 16, 2020	Supplemental Documents	01-Dec-2020	PDF	22-Jan-2021
11	🛃 Master Forms Set	Case Report Forms	15-Jan-2021	PDF	20-Jan-2021
12	🛓 Memorandum: Updated Master Forms Set	Supplemental Documents	15-Jan-2021	PDF	20-Jan-2021
13	Lanuary 2021	Education and Promotion	01-Jan-2021	PDF	11-Jan-2021

S1602 SWOG clinical trial number

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer



Closed Phase	Abbreviated Title	BCG Strain Differences and BCG vaccination in High-Grade Non-Muscle Invasive Bladder Cancer	
	Status Notes	There is a monthly call for coordinators who have questions about this study. Send an email to \$1602question@swog.org to be added.	
100%	Activated	02/07/2017	
	Closed	12/15/2020	(
Accrual	Participants	ALLIANCE, ECOG-ACRIN, NRG, SWOG	
	Study chair(s)	Robert Scott Svatek, MD	

Reports & Approvals
ROS REPORT

#### S1602 Phase III - FDA Registration Trial

#### **Coordinating Group: SWOG**

#### A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

#### **Participants:**

SWOG, CTSU (Supported by Alliance, ECOG-ACRIN, NRG)

#### **Study Chairs:**

R Svatek, A Alva, M Woods (Alliance), V Master (NRG), J Mark (ECOG-ACRIN)

#### Statisticians:

C Tangen, M Plets


#### **Data Coordinators:**

T Johnson, J Jardine

## Date Activated: 02/07/2017

Date Closed: 12/15/2020

#### SCHEMA



## **Research committees**


**Genitourinary Cancer** 

## Treatment

BCG BCG (Tice) BCG Tokyo-172 Strain

## **Other Study Materials**

**Required S1602 Training** 



**Other Clinical Trials** 

## 

#### 2021

The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer [Editorial]

R Li;SP Lerner;A Kamat European Urology Apr;79(4):437-439

PMid: PMID33454163

## 2018

Background and update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer"

R Svatek; C Tangen; S Delacroix; W Lowrance; S Lerner European Urology Focus Jul; 4(4): 522-524

PMid: PMID30197040

## 2017

Bacillus Calmette-Gue'rin manufacturing and SWOG S1602 Intergroup clinical trial [editorial]

JJ Meeks;SP Lerner;RS Svatek Journal of Urology Mar;197(3 Pt 1):538-540; Epub 2016 Dec 16

PMid: PMID27992750 | PMC number: PMC n/a - editorial

# Secondary Analysis of SWOG Data

- Two Options
- Identify your own non-SWOG statistician, fill out a data request, execute a DUA between SWOG and Hutch, get data and conduct analysis, publish in a top journal, be admired by your peers
- Propose an analysis within a SWOG committee, SWOG stats will collaborate with you and conduct the analysis, get a good publication. Resources vary by disease committee. Need to get prioritized.

Title:

Study Chair name/address:

Clinical trial(s) from which data is requested:

Project objective(s):

Primary objective:

Secondary objective(s):

**Brief Justification:** 

Rationale:

Background:

Significance:

Endpoints:

Primary endpoint:

Secondary endpoint(s):

Approach / Methods:

Statistical Plan:

Participating Investigator(s)/Institutions(s) – if collaborative effort:

Data Analysis performed by (and institution/address/contact information):

SWOG data requested:

Patient data from SWOG trial SXXXX. Specific variables requested are:

Expected timeline of Project Completion:

Disclosure of Conflict of Interest:

Financial support of proposal:

References:

- Formulate an objective(s), get local stat support
- Ensure there is no overlap with other work
- Talk to disease committee and/or study leadership about your idea
- Complete a SWOG Data Sharing Form
- Send it to disease stats team for review of feasibility
- Request will be reviewed by SWOG execs
- If approved, a DUA will be executed between your Institution and SWOG for scope of work specified
- Stats send you data




Search Single Trial Data

Search Multi Trial Data

How to Make a Request [PDF]

About Us

Contact Us







# **Translational Studies**




- Get to know the TM chair for your disease committee
- Statistician can help identify sample availability for a given trial.
- TM template used for applying to SWOG Execs.
- Primary (pre-specified) analyses are conducted first.
- Additional analyses on remaining samples up for grabs
- Should be validating, "exploratory" is frowned upon by NCI
- Need a detailed stat analysis plan in the proposal
- TONS of unclaimed samples in the Nationwide Biobank!!





## So you want to coordinate a clinical trial...?





4/27/22 \*\*Anytime after concept approval. TM samples not available until 75% of accrual is reached.







# Incubating a Trial Idea

- Initial presentation floating the concept
- Right fit for NCTN?
- Prioritizing within a committee, can take a few years to move forward
- Feasibility? SWOG's prior experience?
- Complexity? Community participation?
- Investigator reaches out to stats team for initial pass at design considerations
- Include young investigators as part of the team





# Basic Design Considerations (iterative process with study team)

- <u>Target population</u>: impacts accrual rate, generalizability of results, event rate
- <u>Endpoint</u>: Survival, PFS, response -> impacts event rate, duration of trial, sample size
- <u>Treatment effect</u>: The bigger the hypothesized difference between arms -> the smaller sample size, clinically meaningful difference
- <u>Trial duration</u>: potential relevance Clinically meaningful vs. Pragmatic

Median OS	Sample size
12 vs 18 mo	200/arm
12 vs. 16 mo	400/arm
12 vs. 15 mo	600/arm





# X

# NCI Task Force Review – Site specific

- NCI Concept Template is used
- SWOG is staking its claim to a research area
- NCTN disease-specific expertise to review "rough" concept
- Ensure best science, review for overlap with NCTN and pharma
- Other suggestions (TM specimen collection, PROs, imaging)
- Trying to get to "We're supportive of submitting to the Steering Committee"
- Back and forth, less formal than Steering Committee

PS Task Force membership is a good career opportunity





# Statistical Review (aka PRC)

- Weekly meeting in Seattle
- Standards, consistency, clarity
- Statistical principles for design and analysis plans
- Logistical flow of study
- Burden on site and patients
- Shared SWOG knowledge, don't reinvent the wheel





# SWOG Executive Review (aka "Triage")

- Weekly, Monday mornings
- Leaders from all SWOG offices, GCO, Ops, Stats, E.O.s, Advocates
- Is trial scientifically sound? Acceptability of randomization?
- Good use of SWOG resources?
- Fit in disease committee portfolio?
- Burden on sites and patients (e.g., PROs, TM sample collection)
- Extra resources needed? (e.g., FDA registration)
- Rejections are rare, but plenty of review comments





# NCI Steering Committee – Clock starts!

- X
- Polished concept submitted, most logistics, funding worked out
- Formal review with national leaders from NCTN and NCI
- Medical, RT, surgical oncologists, TM experts, advocates, biostatisticians
- Open and closed session
- Unusual to get approved on first try (approve vs. revise and resubmit vs. disapproved)
- SWOG rule: Only 3 on the clock at any given time





# **Concept Approved by Steering Committee**

- "clock starts"
- The fun begins at a fast pace for a lot of people!
- Statistical Team and Operations Office will help with each new step
  - Writing protocol, developing forms, building study in RAVE, testing
  - Monitoring the trial, study chair evaluation forms
  - Stats prepare DSMC reports every six months
  - Abstracts, papers





## THE HOPE FOUNDATION FOR CANCER RESEARCH

- Scientific merit
- Level of engagement in SWOG
- Mentor availability

Career Engagement Award	SWOG BOG Travel Support
Committee Meeting Funds	SWOG Early Exploration & Development (SEED) Fund
CRA/Nurse Travel Support Program	SWOG/Hope Foundation Impact Award
Dr. Charles A. Coltman, Jr. Fellowship Program	SWOG Trial Support (STrS)
Early Stage Investigator Training Course	Trial-Specific Education Funds
The John Crowley, PhD Award	VA Storefront Support Program
NCORP Pilot Grant Program	Virtual Grant Writing Workshop
Secondary Data Analysis	Nicholas Vogelzang SWOG GU Scholarship

Early Stage Investigator Training Course (ESITC)	Multi-day educational intensive in protocol development, trial management, and statistical analysis	Any early career SWOG investigator; includes travel support; see application for details
Dr. Charles A. Coltman Jr. Fellowship Program	<b>\$50,000 x 2 years'</b> salary support - To ensure protected time for new investigators from SWOG-affiliated institutions to pursue mentored clinical research initiatives	Junior faculty* at SWOG member or affiliated institution; <u>see application for</u> <u>details</u> ; <b>includes travel support</b>

## Early Stage Investigator Training Course (ESITC):

The ESITC gives new investigators the opportunity to work 1-on-1 with SWOG's most experienced leaders to develop a rigorous, relevant, and feasible SWOG trial\* concept to launch within the NCI's National Clinical Trials Network. (\*could be TM or complex data analysis)

Involves intensive mentorship and an online course, culminates in a 3-day workshop with SWOG leaders

Course plays a central role in fostering new leadership and ensuring the longevity and legacy of SWOG

Participants are expected to have previous experience within SWOG or make a future commitment to do so. 4 to 6 early stage investigators are selected each year.

All costs for the workshop including travel, ground transportation, meals, lodging, materials, and the workshop itself will be free of charge

**Deadline to apply**: May 1, 2024 **2024 course dates**: typically mid to late September in Seattle

# Get to know your SWOG statisticians

- Happy to meet F2F to discuss potential collaborations
- Guide you through the process of requesting data, samples, conducting analyses, writing abstracts and papers
- Help you navigate a large, complex organization
- Work with you to design a scientifically sound, feasible clinical trial design and support it from initial idea to final publication
- In return, you need to be patient with SWOG's finite resources